Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lenacapavir,Emtricitabine,Tenofovir Disoproxil Fumarate,Tenofovir
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Lenacapavir,Emtricitabine,Tenofovir Disoproxil Fumarate,Tenofovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Burfiralimab,Tenofovir,Entecavir,Trastuzumab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel | Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 21, 2023
Lead Product(s) : Burfiralimab,Tenofovir,Entecavir,Trastuzumab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel | Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenacapavir,Emtricitabine,Tenofovir Disoproxil Fumarate,Tenofovir
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : HIV Prevention Trials Network
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Lenacapavir,Emtricitabine,Tenofovir Disoproxil Fumarate,Tenofovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : HIV Prevention Trials Network
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenacapavir,Emtricitabine,Tenofovir Disoproxil Fumarate,Tenofovir
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : HIV Prevention Trials Network | National Institute on Drug Abuse | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Lenacapavir,Emtricitabine,Tenofovir Disoproxil Fumarate,Tenofovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : HIV Prevention Trials Network | National Institute on Drug Abuse | National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doravirine,Lamivudine,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Africa Health Research Institute | Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Doravirine,Lamivudine,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Africa Health Research Institute | Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABI-H0731 (Vebicorvir) a first-generation selective inhibition of HBV DNA replication core protein, has demonstrated effective antiviral activity in chronic hepatitis B patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doravirine,Lamivudine,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Doravirine,Lamivudine,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : ATI-2173,Tenofovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doravirine,Lamivudine,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Dr. Josep Mallolas
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : Doravirine,Lamivudine,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Dr. Josep Mallolas
Deal Size : Inapplicable
Deal Type : Inapplicable